48
Views
0
CrossRef citations to date
0
Altmetric
CASE REPORT

A Novel Intergenic Region (chr2: 30,316,870)-ALK Fusion in a Patient with Lung Adenocarcinoma Responding to Crizotinib Combined with Pemetrexed Treatment: A Case Report

, , , &
Pages 261-265 | Received 13 Oct 2023, Accepted 19 Mar 2024, Published online: 26 Mar 2024

Figures & data

Figure 1 Schematic of patients’ treatment histories. (A) The treatment timeline of the patient. (B) Images of the chest CT are provided with lung tumors indicated with red arrows.

Abbreviations: LUAD, lung adenocarcinoma; NGS, next-generation sequencing; IGR, intergenic region; PR, partial response; CR, complete response.
Figure 1 Schematic of patients’ treatment histories. (A) The treatment timeline of the patient. (B) Images of the chest CT are provided with lung tumors indicated with red arrows.

Figure 2 Pathology results. (A and B) Hematoxylin-eosin staining of endobronchial ultrasound-guided transbronchial needle aspiration biopsy specimen showed lung adenocarcinoma (10×).

Figure 2 Pathology results. (A and B) Hematoxylin-eosin staining of endobronchial ultrasound-guided transbronchial needle aspiration biopsy specimen showed lung adenocarcinoma (10×).

Figure 3 Sequencing reads of IGR and ALK were visualized by the Integrative Genomics Viewer (IGV). The schematic below shows the IGR (upstream YPEL5-) ALK fusion.

Figure 3 Sequencing reads of IGR and ALK were visualized by the Integrative Genomics Viewer (IGV). The schematic below shows the IGR (upstream YPEL5-) ALK fusion.